These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 18980549)

  • 1. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in the treatment of metastatic colorectal cancer.
    Caprioni F; Fornarini G
    Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Beatty GL; Giantonio BJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
    Krämer I; Lipp HP
    J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
    Grothey A
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M; Roodhart JM; Voest EE
    Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenesis agents in colorectal cancer.
    Hubbard J; Grothey A
    Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis in cancer: clinical development of bevacizumab.
    Kerr DJ
    Nat Clin Pract Oncol; 2004 Nov; 1(1):39-43. PubMed ID: 16264798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L; Claes V; Uzzell M
    Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
    Engstrom PF;
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.